Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (202)

2024

  1. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

    Blood, Vol. 144, Núm. 11, pp. 1193-1205

  2. Correction to: Consumption of soft drinks and juices and risk of liver and biliary tract cancers in a European cohort (European Journal of Nutrition, (2016), 55, 1, (7-20), 10.1007/s00394-014-0818-5)

    European Journal of Nutrition

  3. Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?

    Blood Advances

  4. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  5. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

2023

  1. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778

  2. Cancer data quality and harmonization in Europe: the experience of the BENCHISTA Project – international benchmarking of childhood cancer survival by stage

    Frontiers in Oncology, Vol. 13

  3. Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson’s Disease

    Cells, Vol. 12, Núm. 5

  4. Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study

    British Journal of Cancer, Vol. 128, Núm. 8, pp. 1529-1540

  5. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

    The Lancet Haematology, Vol. 10, Núm. 3, pp. e213-e224

  6. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

    Acta Neuropathologica, Vol. 145, Núm. 5, pp. 651-666

  7. Sweetened beverages are associated with a higher risk of differentiated thyroid cancer in the EPIC cohort: a dietary pattern approach

    European Journal of Nutrition, Vol. 62, Núm. 1, pp. 105-114

2022

  1. A Prospective Diet-Wide Association Study for Risk of Colorectal Cancer in EPIC

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 4, pp. 864-873.e13

  2. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79

  3. Determinants of blood acylcarnitine concentrations in healthy individuals of the European Prospective Investigation into Cancer and Nutrition

    Clinical Nutrition, Vol. 41, Núm. 8, pp. 1735-1745

  4. Genetically Determined Reproductive Aging and Coronary Heart Disease: A Bidirectional 2-sample Mendelian Randomization

    The Journal of clinical endocrinology and metabolism, Vol. 107, Núm. 7, pp. e2952-e2961

  5. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk

    International Journal of Epidemiology, Vol. 51, Núm. 2, pp. 479-490

  6. Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma

    International Journal of Cancer, Vol. 150, Núm. 8, pp. 1255-1268

2021

  1. Adiposity and endometrial cancer risk in postmenopausal women: A sequential causal mediation analysis

    Cancer Epidemiology Biomarkers and Prevention, Vol. 30, Núm. 1, pp. 104-113

  2. Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

    Pediatric Blood and Cancer, Vol. 68, Núm. S4